Fatality Rate and Risk Factors Related to Mortality of Persistent Pulmonary Hypertension of the Newborn (PPHN) in Sisaket Hospital
Article Sidebar
Main Article Content
Abstract
Background: Persistent pulmonary hypertension of the newborn (PPHN) is the most serious condition in infants resulting in a high morbidity and mortality
Objective: To determine fatality rate and risk factors related to mortality of Persistent Pulmonary Hypertension of the Newborn (PPHN) in Sisaket Hospital
Methods: A retrospective cohort study of patient who were treated with persistent Pulmonaryhypertension of the newborn(PPHN) at Sisaket hospital from 1st January 2015 to 31st December 2020. Data collected from medical records.
Results: A total number of 84 infants with PPHN were identified (2.9 per thousand lived birth). The male to female ratio was 1.6:1. There were 46.4% delivered by cesarean section. The average gestational age were 37.9±2.3 weeks, birth weight 2913.3±647 grams. The fatality rate of PPHN was 64%. The most common maternal problem was meconium stain amniotic fluid (33.3%). The most common initial diagnosis was congenital pneumonia (42.9%). All infants were treated with high frequency oscillatory ventilation (HFOV). Maximum mean airway pressure (MAP) and delta P in HFOV setting were 19.3±4.5cmH2O and 46.5±10.9cmH2O respectively. The most common complication was hospital acquired pneumonia (42.9%). The risk factors related with mortality in PPHN were meconium aspiration syndrome (odds ratio 4.136, P 0.019) and maximum mean airway pressure (MAP) in HFOV ≥ 20cmH2O (odds ratio 7.368, P 0.015)
Conclusion: The fatality rate of PPHN was 64%. The risk factors related with mortality in PPHN were meconium aspiration syndrome and maximum mean airway pressure (MAP) in HFOV ≥ 20 cmH2O
Keywords: Persistent pulmonary hypertension of the newborn, fatality rate, risk factor
Article Details
References
Oishi PE, Keller RL. When persistent pulmonary hypertension of the newborn persists. Pediatr Crit Care Med 2012;13(2):224-5.
Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med 2010;11(2 Suppl):S79-84.
Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105(1 Pt 1):14-20.
Roofthooft MT, Elema A, Bergman KA, Berger RM. Patient characteristics in persistent pulmonary hypertension of the newborn. Pulm Med 2011;2011:858154.
Steurer MA, Jelliffe-Pawlowski LL, Baer RJ, Partridge JC, Rogers EE, Keller RL. Persistent Pulmonary Hypertension of the Newborn in Late Preterm and Term Infants in California. Pediatrics 2017;139(1):e20161165.
วรนาฏ จันทร์ขจร, อำนวยพร อภิรักษากร. ผลการรักษาภาวะความดันเลือดปอดสูงในทารกแรกเกิดในโรงพยาบาลตติยภูมิ. วารสารกุมารเวชศาสตร์ 2563;59(2):131-8.
Mathew B, Lakshminrusimha S. Persistent Pulmonary Hypertension in the Newborn.Children (Basel) 2017;4(8):63.
Jain A, McNamara PJ. Persistent pulmonary hypertension of the newborn: Advances in diagnosis and treatment. Semin Fetal Neonatal Med 2015;20(4):262-71.
Razzaq A, IqbalQuddusi A, Nizami N. Risk factors and mortality among newborns with persistent pulmonary hypertension.Pak J Med Sci 2013;29(5):1099-104.
Nakwan N, Jain S, Kumar K, Hosono S, Hammoud M, Elsayed YY, et al. An Asian multicenter retrospective study on persistent pulmonary hypertension of the newborn: incidence, etiology, diagnosis, treatment and outcome. J Matern Fetal Neonatal Med 2020;33(12):2032-2037.
ธีรศักดิ์ อุดมศรี. การศึกษาภาวะความดันหลอดเลือดปอดสูงในทารกแรกเกิดในโรงพยาบาลกระบี่. กุมารเวชสาร 2558;22(1):23-30.
นพวรรณ พงศ์โสภา. ภาวะความดันเลือดในปอดสูงในทารกแรกเกิด โรงพยาบาลสุราษฎร์ธานี. วารสารวิชาการแพทย์เขต 11 2560;31(1):49-59.
Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006;117(4):1077-83.
Kahveci H, Yilmaz O, Avsar UZ, Ciftel M, Kilic O, Laloglu F, et al. Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn. Pediatr Pulmonol 2014;49(12):1205-13.
Janjindamai W, Thatrimontrichai A, Maneenil G, Chanvitan P, Dissaneevate S. Effectiveness and safety of intravenous iloprost for severe persistent pulmonary hypertension of the newborn. Indian Pediatr 2013;50(10):934-8.
Jaroensri S, Kamolvisit W, NakwanN.Risk factor analysis of pneumothorax associated with persistent pulmonary hypertension of the newborn in Thai neonates. J Matern Fetal Neonatal Med 2020;33(24):4090-5.
Nakwan N, Pithaklimnuwong S. Acute kidney injury and pneumothorax are risk factors for mortality in persistent pulmonary hypertension of the newborn in Thai neonates. J Matern Fetal Neonatal Med 2016;29(11):1741-6.
Mat Bah MN, Tan RYH, Razak H, Sapian MH, Abdullah N, Alias EY. Survival and associated risk factors for mortality among infants with persistent pulmonary hypertension of the newborn in Malaysia. J Perinatol 2021;41(4):786-793.
Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment. Semin Perinatol 2014;38(2):78-91.
